Seventeen patients with hyperuricemia accompanied with urolithiasis (8 with gout,9 without gout) were treated favorably with longterm administration of allopurinol for about 5 years to 10 years. No urolithiasis recurred throughout the therapeutic period. Of 17 patients,14 were hyperuricosuric and 3 normouricosuric. All patients were, however, normocalcemic. Calculus was recovered from 13 patients, which was according to the infrared spectra chiefly composed of calcium oxalate or phosphate in 9 patients (about 69 per cent). This means that allopurinol should be effective in the treatment of hyperuricosuric calcium urolithiasis. Depend on chemical composition of our cases, urinary tract stones accompanied with hyperuricemic patients were not always uric acid. It is recommended to analyze the underlying stone as far as possible for controlling the urinary pH value correspondingly to the nature of the stone.
The pharmacological studies of CG-120 (Uralyt-U) were investigated, in rats. The rise of urinary pH which was indicated by both CG-120 and sodium bicarbonate (NaHCO3) paralleled the increase of urinary HCO3- concentration. This result seemed that the alkalogenic effects of CG-120 and NaHCO3 on urine were caused by the increase of urinary HCO3- concentration. In addition, the sustained times of both agents were approximately the same, but in comparison with NaHCO3, CG-120 did not show the acute rise of urinary pH and the sudden increase of urinary HCO3- concentration. This observation suggested that CG-120 may be more safely for the organism as compared with NaHCO3. On the other hand, the rise of urinary pH and the increase of urinary uric acid excretion were observed when CG-120 was respectively administrated together with furosemide, allopurinol and benzbromarone. These results suggest that CG-120 may be useful agent for the subsidiary therapy of hyperuricemias.
(1) Among the examinees for hospitalized physical checkup, fewer examinees on. Biloptin (sodium ipodate) medication were found hyperuricemic than those with no history of this medication. (2) The average serum urate concentration in the examinees for hospitalized physical checkup who were found normal in every checkup parameter was 4.533 mg/dl for the men and 3.610 mg/dl for the women on Biloptin medication, and 5.387 mg/dl for the men and 4.063 mg/dl for the women with no history of this medication. (3) Among the gout patients admitted for hospitalized physical checkup, those on Biloptin medication included a smaller ratio of hyperuricemic patients than those with no history of this medication. (4) The examinees for hospitalized physical checkup were medicated orally with 6 tablets of Biloptin, respectively, and 12 hours later the serum urate, serum total bilirubin and blood sugar were determined. Of these findings, the serum urate was decreased, and the serum total bilirubin and blood sugar were elevated, compared with these parameters determined about 1 month later. (5) Oral medication with Biloptin gives rise to urate diuresis. This medication therefore results in a decrease in serum urate concentration. Biloptin has proved to cause false negative or positive results of some blood biochemical tests, which needs to be carefully considered in designing a laboratory study for the patient on this medication.
Association between hyperuricemia and obesity, hypertriglyceridemia, hypercholesterolemia, habitual alcohol intake and hyperglycemia was studied on 2,264 male employees of various enterprises. The prevalence of hyperuricemia and the mean serum uric acid levels in cases with any one of these variables, except for hyperglycemia, were higher than those with no variables. These results indicate that each variable, except for hyperglycemia, is related independently to hyperuricemia. 81 cases out of 219 with hyperuricemia (36.9%) were associated with two or more variables, and 101 cases (46.1%) were associated with a single variable. 137 cases out of 219 with hyperuricemia (62.5%) were associated with habitual alcohol intake,84 cases (38.3%) with obesity and 50 cases (22.8%) with hypertriglyceridemia.